Aim: The quality of drug clinical trials is crucial for authorizing new drugs and fostering innovations in clinical practice. This study aimed to report the status, trends, and factors of the quality of drug clinical trials in China.
Methods: This mixed methods study assessed trial quality using quantitative data from public sources and qualitative data from focus groups and interviews with key stakeholders.
Results: The No Action Indicated findings issued by the Food and Drug Administration increased from 43% from 2009–2015 to 88% from 2016–2022, whereas the Official Action Indicated findings decreased from 9% to 0% (p = 0.001). The Center for Food and Drug Inspection revealed that 12% of new drug applications in 2015–2017 were suspected of data fabrication, compared to only 0.6% failed to pass the inspection in 2022 (p < 0.001). Number of drug trials published by Chinese institutions in top medical journals increased from 1.3% in 2009 to 4.9% in 2022 (p for trend <0.001). Moreover, the number of clinical trial guidelines increased from approximately 10/year from 2015–2019 to 50–60/year from 2020–2022, number of internationally accredited ethics committees increased from 4 in 2009 to 82 in 2022, and over 130,000 individuals received training on the International Council for Harmonization guidelines. Interviews with stakeholders revealed a consensus on quality improvement, attributed to seven key factors, and highlighted further recommendations to enhance clinical trial quality in China.
Conclusions: The quality of drug clinical trials in China has significantly improved over the past decade, yet there remains scope for further enhancement.
| [1] |
R. Collins, L. Bowman, M. Landray, and R. Peto, “The Magic of Randomization Versus the Myth of Real-World Evidence,” New England Journal of Medicine 382, no. 7 (2020): 674–678.
|
| [2] |
R. Collins and S. MacMahon, “Reliable Assessment of the Effects of Treatment on Mortality and Major Morbidity, I: Clinical Trials,” Lancet 357, no. 9253 (2001): 373–380.
|
| [3] |
M. J. Landray, J. J. Bax, L. Alliot, et al., “Improving Public Health by Improving Clinical Trial Guidelines and Their Application,” European Heart Journal 38, no. 21 (2017): 1632–1637.
|
| [4] |
J. A. DiMasi, L. Feldman, A. Seckler, and A. Wilson, “Trends in Risks Associated with New Drug Development: Success Rates for Investigational Drugs,” Clinical Pharmacology & Therapeutics 87, no. 3 (2010): 272–277.
|
| [5] |
J. W. Sellers, C. M. Mihaescu, K. Ayalew, et al., “Descriptive Analysis of Good Clinical Practice Inspection Findings From U.S. Food and Drug Administration and European Medicines Agency,” Therapeutic Innovation & Regulatory Science 56, no. 5 (2022): 753–764.
|
| [6] |
E. H. Rubin and D. G. Gilliland, “Drug Development and Clinical Trials—The Path to an Approved Cancer Drug,” Nature reviews Clinical oncology 9, no. 4 (2012): 215–222.
|
| [7] |
X. Luo, X. Du, L. Huang, et al., “Evidence of Pre-Approval Clinical Trial Supporting the Granted Conditional Approval for Novel Cancer Drugs in China Between 2015 and 2022,” EClinicalMedicine 63 (2023): 102177.
|
| [8] |
Y. Wu, D. Yin, and K. Abbasi, “China's Medical Research Revolution,” Bmj 360 (2018): k547.
|
| [9] |
H. Huang, D. Wu, H. Miao, et al., “Accelerating the Integration of China Into the Global Development of Innovative Anticancer Drugs,” The Lancet Oncology 23, no. 11 (2022): e515–e520.
|
| [10] |
P. K. Drain, M. Robine, K. K. Holmes, and I. V. Bassett, “Trial Watch: Global Migration of Clinical Trials,” Nature Reviews Drug Discovery 13, no. 3 (2014): 166–167.
|
| [11] |
A. Mullard, “Chinese Biopharma Starts Feeding the Global Pipeline,” Nature Reviews Drug Discovery 16, no. 7 (2017): 443–446.
|
| [12] |
E. Fountzilas, A. M. Tsimberidou, H. H. Vo, and R. Kurzrock, “Clinical Trial Design in the Era of Precision Medicine,” Genomic Medicine 14, no. 1 (2022): 101.
|
| [13] |
Central People's Government of the People's Republic of China. Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices 2017 [cited 2024 April 22], https://www.gov.cn/zhengce/2017-10/08/content_5230105.htm.
|
| [14] |
Central People's Government of the People's Republic of China. Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices 2015 [cited 2024 April 22], https://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm.
|
| [15] |
Center for Drug Evaluation. China Drug Trials Website 2024 [cited 2024 December 24], http://www.chinadrugtrials.org.cn/index.html.
|
| [16] |
M. Woodhead, “80% of China's Clinical Trial Data Are Fraudulent, Investigation Finds,” Bmj 355 (2016): i5396.
|
| [17] |
M. D. Fetters, L. A. Curry, and J. W. Creswell, “Achieving Integration in Mixed Methods Designs—Principles and Practices,” Health Services Research 48, no. 6 Pt 2 (2013): 2134–2156.
|
| [18] |
Center for Food and Drug Inspection of NMPA. Interim Report On Drug Clinical Trial Data Inspection 2017 [cited 2025 February 11], https://www.cfdi.org.cn/resource/attachment/ueFile/2017/07/RnJpIEp1bCAyMSAxNDoxNDo0MyAyMDE3NjYxMzU=.pdf.
|
| [19] |
C. Yao, “Clinical Trial in China: The Status and Challenge of Data Management and Statistical Analysis,” Journal of Evidence-Based Medicine 11, no. 1 (2018): 3–6.
|
| [20] |
Center for Food and Drug Inspection of NMPA. 2022 Annual Drug Inspection Report 2023 [cited 2024 October 7], https://www.cfdi.org.cn/resource/news/15638.html.
|
| [21] |
Center for Drug Evaluation. ICH Guidelines 2024 [cited 2024 November 1], https://www.cde.org.cn/ichWeb/guideIch/toGuideIch/5/1.
|
| [22] |
Center for Food and Drug Inspection of NMPA. China's Drug Clinical Trial Institution Record-Keeping System 2024 [cited 2024 November 1], https://beian.cfdi.org.cn/CTMDS/apps/pub/drugPublic.jsp.
|
| [23] |
DIA. ICH Theme Day | China Enters a New Era in ICH 2022 [cited 2024 December 18], https://www.diaglobal.org.cn/newsinfo/4856882.html?templateId=1793749.
|
| [24] |
Xinhua News Agency. Establishment of 50 National Clinical Research Centers in China 2022 [cited 2025 February 11], https://www.gov.cn/xinwen/2022-08/25/content_5706815.htm.
|
| [25] |
Xinhua News Agency. China Establishes 13 Specialized National Medical Centers 2023 [cited 2025 February 11], https://www.gov.cn/lianbo/2023-04/13/content_5751357.htm.
|
| [26] |
National Health Commission. Ethical Review Measures for Life Science and Medical Research involving Humans 2023 [cited 2024 March 9], https://www.gov.cn/zhengce/zhengceku/2023-02/28/content_5743658.htm.
|
| [27] |
National Medical Products Administration. Procedures for Supervision Inspection of Drug Clinical Trial Institutions (Trial) 2023 [cited 2024 December 28], https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20231103175749117.html.
|
| [28] |
H. Huang, Y. Hou, H. Fang, et al., “Unveiling Quality of Clinical Trial in China: From Concern to Confirmation,” Cancer Communications (London, England) 44, no. 5 (2024): 576–579.
|
| [29] |
H. Fang, Y. R. Hou, H. Y. Huang, et al., “International Comparison and Assessment of the Quality of Drug Clinical Trial Implementation in China Based on Scientific Regulatory System,” Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 45 (2023): 1–7.
|
| [30] |
K. Ayalew, Y. M. Ning, M. J. Foringer, et al., “Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency,” Therapeutic Innovation & Regulatory Science 57, no. 1 (2023): 79–85.
|
| [31] |
Y. Ma, Q. Wang, Y. Duan, et al., “Promoting the Quality and Transparency of Health Research in China,” Journal of Clinical Epidemiology 152 (2022): 209–217.
|
| [32] |
S. H. Bradley, K. E. Lloyd, and N. J. DeVito, “Automatic Registration for UK Trials,” Bmj 376 (2022): o41.
|
| [33] |
R. Dal-Ré, A. S. Kesselheim, and F. T. Bourgeois, “Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials,” Jama 323, no. 19 (2020): 1903–1904.
|
| [34] |
Y. Zhu, X. Sun, M. Cai, J. Shi, and X. Li, “Construction of a Competency Evaluation Model for Clinical Research Coordinators in China: A Study Based on the Delphi Method and Questionnaire Survey,” BMJ Open 14, no. 9 (2024): e083957.
|
| [35] |
J. Ge, Y. Liu, B. Gan, et al., “Expert Consensus on Clinical Research Nurse Management in China,” Asia-Pacific Journal of Oncology Nursing 10, no. 9 (2023): 100254.
|
| [36] |
L. Chen, Z. Chen, and H. Chen, “The Appearance and Increase in the Quantity and Proportion of the Clinical Research Coordinator's Service Fee in Drug Clinical Trial Research Fund and Its Impact on Trial Quality,” Cost-Effectiveness and Resource Allocation 19, no. 1 (2021): 41.
|
| [37] |
X. Y. Han, X. Li, N. Liang, et al., “Factors Influencing the Quality of Clinical Trials on Traditional Chinese Medicine-Qualitative Interviews With Trial Auditors, Clinicians and Academic Researchers,” Complementary Therapies in Clinical Practice 37 (2019): 109–114.
|
| [38] |
A. K. Feehan and J. Garcia-Diaz, “Investigator Responsibilities in Clinical Research,” Ochsner Journal 20, no. 1 (2020): 44–49.
|
| [39] |
N. Huang, W. Huang, Y. Luo, and J. Huang, “China's Drug Clinical Trial Institution Record-Keeping System: Qualification Requirements for PI Are the Key,” Frontiers in pharmacology 14 (2023): 1052977.
|
| [40] |
Y. Zhao, Q. Yang, and X. Zhang, “Quality of Phase I Clinical Drug Trials: Influence of Organizational Management Factors,” Journal of Clinical Pharmacy and Therapeutics 45, no. 5 (2020): 968–975.
|
| [41] |
X. Niu, D. Zhang, L. Xu, et al., “Enhancing Quality and Efficiency of Clinical Trial Management in Hospitals by Quality Management System,” The Chinese Journal of Clinical Pharmacology 35, no. 15 (2019): 1689–1691.
|
| [42] |
H. Huang, N. Jiang, W. Chen, Y. Tang, and N. Li, “A Call to Rethink the Necessity of and Challenges Facing Academic Research Organizations in the New Era of Drug Innovation in China,” Drug Discovery Today 29, no. 4 (2024): 103925.
|
| [43] |
D. Xu and B. C. Xing, “Quality Over Quantity: A Necessary Path for Clinical Research Transformation in China,” Hepatobiliary Surgery and Nutrition 9, no. 5 (2020): 684–686.
|
| [44] |
J. Cimino and C. Braun, “Building a Competitive Infrastructure to Support Clinical Research in Healthcare Institution,” European Journal of Clinical Investigation 51, no. 9 (2021): e13641.
|
| [45] |
L. McNair, “Ethical and Regulatory Oversight of Clinical Research: The Role of the Institutional Review Board,” Experimental Biology and Medicine (Maywood, NJ) 247, no. 7 (2022): 561–566.
|
| [46] |
J. Ding, Y. Yin, K. Fang, W. Zhang, and S. Luo, “A Narrative Review on the Development of the Ethical Review Mode of Multicenter Clinical Trials in China,” Annals of translational medicine 10, no. 22 (2022): 1251.
|
| [47] |
J. Bechtel, T. Chuck, A. Forrest, et al., “Improving the Quality Conduct and Efficiency of Clinical Trials With Training: Recommendations for Preparedness and Qualification of Investigators and Delegates,” Contemporary Clinical Trials 89 (2020): 105918.
|
| [48] |
K. A. Getz, J. Wenger, R. A. Campo, E. S. Seguine, and K. I. Kaitin, “Assessing the Impact of Protocol Design Changes on Clinical Trial Performance,” American Journal of Therapeutics 15, no. 5 (2008): 450–457.
|
| [49] |
A. Meeker-O'Connell, C. Glessner, M. Behm, et al., “Enhancing Clinical Evidence by Proactively Building Quality Into Clinical Trials,” Clinical Trials 13, no. 4 (2016): 439–444.
|
| [50] |
A. Meeker-O'Connell and C. Glessner, “Clinical Trial Quality: From Supervision to Collaboration and Beyond,” Clinical Trials 15, no. 1_suppl (2018): 23–26.
|
| [51] |
A. Magnin, V. C. Iversen, G. Calvo, et al., “European Survey on National Training Activities in Clinical Research,” Trials 20, no. 1 (2019): 616.
|
| [52] |
G. T. Clark, R. Mulligan, and K. Baba, “Developing and Providing an Online (Web-Based) Clinical Research Design Course in Japan: Lessons Learned,” Journal of Prosthodontic Research 55, no. 2 (2011): 61–68.
|
| [53] |
M. Hutson, “How AI Is Being Used to Accelerate Clinical Trials,” Nature 627, no. 8003 (2024): S2–S5.
|
| [54] |
H. Chopra, Annu, D. K. Shin, et al., “Revolutionizing Clinical Trials: The Role of AI in Accelerating Medical Breakthroughs,” International Journal of Surgery 109, no. 12 (2023): 4211–4220.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.
PDF
